Cytomegalovirus Treatment Market Is Likely to Experience a Tremendous Growth by 2029

The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%–56.0% in SOT recipients and 30.0%–70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in Europe and neighboring countries in 2019. Thus, the growing drug approval for its treatment is a key factor driving the growth of the global cytomegalovirus treatment market.

For instance, in September 2022, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

In August 2022, Florida, US-based firm Fortress Biotech has been awarded a $20 million grant to develop its cytomegalovirus vaccine Triplex. Under development by its subsidiary Helocyte, Triplex is a universal viral vector vaccine, which has been engineered to induce a cytomegalovirus -specific T cell response. In previous Phase I and Phase II studies, it has been found to be safe, well-tolerated and immunogenic. Helocyte has secured an exclusive worldwide license to Triplex from its originator, City of Hope cancer research center.Fortress plans to test its candidate across up to 15 transplant centers in the US. Triplex was developed by City of Hope, one of the largest cancer research and treatment organizations in the US. Development of cytomegalovirus vaccine may restrain the global cytomegalovirus treatment market.

To Request a Sample of our Report on Cytomegalovirus Treatment Market:  https://www.omrglobal.com/request-sample/cytomegalovirus-treatment-market

Market Coverage

             The market number available for – 2022-2030

             Base year- 2022

             Forecast period- 2023-2030

Segment Covered- 

                 By Drug Type

                 By Application

                 By Distribution Channel

Regions Covered-

                 North America

                 Europe

                 Asia-Pacific

                 Rest of the World

Competitive Landscape- including F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others.

A full Report of Cytomegalovirus Treatment Market is Available @  https://www.omrglobal.com/industry-reports/cytomegalovirus-treatment-market

Cytomegalovirus Treatment Market Report Segment

By Drug Type

                 Cidofovir

                 Foscarnet

                 Valganciclovir 

                 Ganciclovir

By Application

                 Stem Cell Transplantation

                 Organ Transplantation

                 Congenital CMV Infection

                 Other Application

By Distribution Channel

                 Hospital pharmacies

                 Retail Pharmacies

                 E-commerce

Cytomegalovirus Treatment Market Report Segment by Region

North America                                                                                                           

·        United States

·        Canada                     

Europe

·        UK

·        Germany

·        Spain

·        France

·        Italy

·        Rest of Europe

Asia-Pacific

·                  India

·                  China

·                  Japan              

·                  South Korea

·                  Rest of APAC

Rest of the World

       Latin America

       Middle East and Africa 

Company Profiles

                 AiCuris Anti-infective Cures GmbH 

                 Chimerix, Inc.

                 Clinigen Group PLC 

                 F. Hoffmann-La Roche AG 

                 Fresenius Kabi Canada 

                 Genentech Inc.

                 Gilead Sciences, Inc.

                 GlaxoSmithKline plc 

                 Merck & Co., Inc. 

                 Moderna, Inc.

                 Mylan N.V

                 Pfizer Inc.

                 Takeda Pharmaceuticals

                 Teva Pharmaceuticals Inc

                 Thermo Fisher Scientific, Inc.

                 Vical, Inc. 

                 ViroPharma, Inc.

Reasons to buy from us –

1.  We cover more than 15 major industries, further segmented into more than 90 sectors.

2.  More than 120 countries are for analysis.

3.  Over 100+ paid data sources mined for investigation.

4.  Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/cytomegalovirus-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no:  +91 7803040404

Comments

Popular posts from this blog

European Data Backup and Recovery Market Size, Share, Analysis, Industry Report and Forecast 2019-2025

Insect Repellent Market Is Likely to Experience a Tremendous Growth by 2031

Asia-Pacific Urban Air Mobility Market Growth, Size, Share, Industry Report and Forecast 2019-2025